Crucell corporate brochure (PDF)

More documents

Recommendations

Info

22 Our business – Technologies Our cutting-edge technologies Crucell’s strong product portfolio is supported by a range of patented technologies. Our cutting-edge technology platforms enable the cost-effective discovery, development and production of a range of biopharmaceutical products, including innovative vaccines, therapeutic proteins and gene therapies. In therapeutic areas where Crucell does not plan to develop its own products, these proprietary technologies may be licensed out to other biopharmaceutical manufacturers or research groups. 5 core platforms www.crucell.com Core proprietary technology platforms Crucell has five core proprietary technology platforms, and two support technologies developed by Crucell to facilitate biopharmaceutical innovation: 1. PER.C6® technology: a comprehensive package of technology and know-how based on our PER.C6® human cell line. It provides a safe and cost-effective manufacturing system for high-yield, large-scale production of vaccines, recombinant proteins including monoclonal antibodies, and gene therapy products. 2. AdVac® technology: a technology based on the development and production of novel adenovirus vectors. It can be used together with PER.C6® technology to develop recombinant vaccines against life-threatening diseases or to develop gene therapy products. 3. MAbstract® technology: a human-based antibody phage display technology that facilitates the discovery of novel drug targets and the identification of human monoclonal antibodies against those targets. 4. STAR® technology: a gene expression technology that enhances yields of recombinant human antibodies and therapeutic proteins on mammalian cells lines. 5. Virosome technology: a virosome is a virus-like particle that acts as a vaccine adjuvant and carrier system. Vaccines based on virosome technology combine high efficacy with high purity, and therefore low potential for causing side effects. Support technologies A. Recombinant Paramyxovirus technology: a novel vaccine design technology based on recombinant measles vectors. These vaccine vectors can be manufactured economically in large quantities, and induce strong and sustained immune responses against the antigens they carry. B. Hansenula polymorpha technology: an innovative yeast-based production platform widely used for the manufacture of industrial proteins, food and feed additives, and highly immunogenic vaccines— such as Crucell’s Hepavax-Gene® vaccine against hepatitis B.
Our business – Technologies PER.C6® technology: an innovative package The PER.C6® human cell line is the cornerstone on which Crucell was built. It was originally developed for making antibodies against cancer and for gene therapy, but around 2002 researchers in the company discovered that a wide range of viruses also grow very well on PER.C6®. This meant that PER.C6® could be developed as a platform for producing the new viral vaccines the world needs—classical as well as adenovirus-based vaccines. PER.C6® technology offers major advantages over other platforms used for manufacturing biological products and is uniquely positioned to meet the key challenges in the industry. These include the need to produce larger volumes of product more quickly and cost-effectively, while meeting increasingly stringent safety requirements. The heart of PER.C6® technology is the PER.C6® human cell line. This is a continuously dividing set of cells derived from a single human cell, immortalized using recombinant DNA technology. Like other continuous cell lines, PER.C6® cells can replicate indefinitely— but that is where the comparison ends. One of the great advantages of PER.C6® cells is that they grow to much higher density than other continuous cell lines. This is due to inherent characteristics of the PER.C6® cells themselves, which are further enhanced by the intensified manufacturing process and special growth media developed as part of the PER.C6® technology package. The ability of PER.C6® cells to grow to exceptionally high densities means that much more biological product can be harvested from much smaller bioreactors. For example, PER.C6® cells infected with virus for manufacturing purposes produce at least 10 times more virus per milliliter than any other cell line does. The same yield can therefore be obtained from a 500-liter bioreactor using PER.C6® as a 5000-liter or larger bioreactor using another cell line. This translates into significant savings in capital expenditure and production costs, as well as shorter production times. PER.C6® technology is an ideal companion for other innovative Crucell technologies, such as the virosome (a vaccine design technology combining high efficacy with low side effects) and AdVac® technology (which focuses on the development of novel adenovirus vectors and is used with PER.C6® to develop recombinant vaccines). 27 g/L Record-level titer achieved at harvest for an antibody product using PER.C6® human cell line technology. 10 times More virus per millimeter are produced by PER.C6® infected cells. 23
Page 1 and 2: Bringing innovation to global healt
Page 3 and 4: 2010 key highlights Revenues and ot
Page 5 and 6: Overview - Crucell at a glance Cruc
Page 7 and 8: Overview - Crucell at a glance broa
Page 9 and 10: Overview - Crucell: A global perspe
Page 11 and 12: Overview - Message from our CEO and
Page 13 and 14: Our business - Research and develop
Page 23: Our business - Technologies Crucell
Page 27 and 28: Our business - Technologies MAbstra
Page 29 and 30: Our business - Products Crucell foc
Page 31 and 32: Our business - Products Cases of di
Page 33 and 34: Our business - Products areas as we
Page 35 and 36: Crucell’s commitment to the world
Page 75 and 76:
Crucell’s commitment to the world
Page 77:
Crucell’s commitment to the world
Page 80:
www.crucell.com Newtonweg 1 2333 CP
show all

Crucell corporate brochure (PDF)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?